# Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT

> **NCT04624828** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Istituto Clinico Humanitas** · enrollment: 40 (estimated)

## Conditions studied

- Oligorecurrent and Oligoprogressive Prostate Cancer Patients

## Interventions

- **PROCEDURE:** Radiotherapy
- **DRUG:** androgen deprivation therapy (ADT)
- **BIOLOGICAL:** immune evaluation

## Key facts

- **NCT ID:** NCT04624828
- **Lead sponsor:** Istituto Clinico Humanitas
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-19
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04624828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04624828, "Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04624828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*